BA
NWBO

Bristlecone Advisors’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Bristlecone Advisors’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,075
Closed – – 284
2017
Q3 		$0 Buy
+1,075
New – ﹤0.01% 293

Other funds holding NWBO

LDB
Lee, Danner & Bass Nashville, Tennessee $1.73B AUM 36.69% 1-Year Est. Return
WPP
Whalerock Point Partners Providence, Rhode Island $518M AUM 25.26% 1-Year Est. Return
MPI
Mairs & Power Inc St Paul, Minnesota $9.79B AUM 20.6% 1-Year Est. Return

Bristlecone Advisors's NWBO Position: Q4 2017 in Review

Bristlecone Advisors sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q4 2017, closing a stake of 1,075 shares.

Bristlecone Advisors first reported a position in NWBO in Q3 2017 and held it in 1 quarter. The position peaked at $0 in Q3 2017. 4 funds tracked by Wall St. Rank hold NWBO as of Q4 2017.

  • Bristlecone Advisors reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q4 2017 after selling out during the quarter.
  • Bristlecone Advisors sold 1,075 Northwest Biotherapeutics, Inc. Common stock shares in Q4 2017.
  • Bristlecone Advisors first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q3 2017 and held it in 1 quarter.
  • Bristlecone Advisors's Northwest Biotherapeutics, Inc. Common stock position peaked at $0 in Q3 2017.
  • 4 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q4 2017.

Based on Bristlecone Advisors's 13F filing for Q4 2017, filed 30 Jan 2018.